COMPANY RESEARCHAlnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a United States biopharmaceutical company focused on the discovery, development and commercialization of medicines based on RNA interference. Its technology is designed to reduce production of selected disease related proteins through gene silencing. The company develops and markets therapeutics for serious conditions, including rare genetic and cardiovascular diseases, and collaborates with other pharmaceutical companies in selected programs. Founded in 2002, Alnylam is headquartered in Cambridge, Massachusetts. Its official website and investor relations pages provide information on currently marketed medicines, investigational programs, scientific publications and corporate disclosures.
Company at a glance
Corporate information
- Company entity
- Alnylam Pharmaceuticals
- Headquarters / principal office
- Cambridge, Massachusetts, United States
Sources (1)
- Official company history / founding disclosureUndated; checked 2026-11-04
- Founded
- 2002
Sources (1)
- Official company history / founding disclosureUndated; checked 2026-11-04
- Ownership / capital status
- Publicly tradedNasdaq ALNY
Sources (1)
- Official company history / founding disclosureUndated; checked 2026-11-04
- Official corporate reference
- https://www.alnylam.com/
Sources (1)
- Alnylam Pharmaceuticals — official website2026-11-04 retrieval
- LinkedIn company page
- LinkedIn ↗
Sources (1)
- Corporate website links to the company LinkedIn pageChecked 2026-11-04; source publication date retained where stated
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Alnylam Pharmaceuticals is a United States biopharmaceutical company focused on the discovery, development and commercialization of medicines based on RNA interference. Its technology is designed to reduce production of selected disease related proteins through gene silencing. The company develops and markets therapeutics for serious conditions, including rare genetic and cardiovascular diseases, and collaborates with other pharmaceutical companies in selected programs. Founded in 2002, Alnylam is headquartered in Cambridge, Massachusetts. Its official website and investor relations pages provide information on currently marketed medicines, investigational programs, scientific publications and corporate disclosures.
Nasdaq: ALNY
RNA interference · RNA therapeutics
rare diseases · cardiovascular · neurology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Alnylam develops RNA interference medicines and presents its delivery platforms, marketed products, clinical programs, and scientific materials on its official website. This profile identifies a drug developer, rather than a contract service provider.
Business, technology & evidence
- Alnylam Pharmaceuticals is a United States biopharmaceutical company focused on the discovery, development and commercialization of medicines based on RNA interference. Its technology is designed to reduce production of selected disease related proteins through gene silencing. The company develops and markets therapeutics for serious conditions, including rare genetic and cardiovascular diseases, and collaborates with other pharmaceutical companies in selected programs. Founded in 2002, Alnylam is headquartered in Cambridge, Massachusetts. Its official website and investor relations pages provide information on currently marketed medicines, investigational programs, scientific publications and corporate disclosures.
- SecuritiesNasdaq: ALNY
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| AMVUTTRA / vutrisiran | TTR · Adult hATTR polyneuropathy; adult wild-type or hereditary ATTR cardiomyopathy | 美国获批 | Human/approved evidence; see original source for scope |
| ONPATTRO / patisiran | TTR · Adult hATTR polyneuropathy | 美国获批 | Human/approved evidence; see original source for scope |
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Two representative programs added; not a complete pipeline. Later developments, registry status and other indications remain to be checked.
- Alnylam Pharmaceuticals — official website ↗Alnylam Pharmaceuticals · 2026-11-04 retrieval
- AMVUTTRA US prescribing information ↗Alnylam Pharmaceuticals · 2025-03
- ONPATTRO US prescribing information ↗Alnylam Pharmaceuticals · 2025-09
- Official issuer and R&D disclosure · Alnylam Pharmaceuticals, Inc. ↗Alnylam Pharmaceuticals, Inc. ·
- Official issuer and R&D disclosure · Alnylam Pharmaceuticals, Inc. ↗Alnylam Pharmaceuticals, Inc. ·
- Official issuer and R&D disclosure · Alnylam Pharmaceuticals, Inc. ↗Alnylam Pharmaceuticals, Inc. ·
- Official issuer and R&D disclosure · Alnylam Pharmaceuticals, Inc. ↗Alnylam Pharmaceuticals, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.